The primary purpose of this placebo-controlled study is to evaluate the low‐density lipoprotein cholesterol (LDL‐C) efficacy and dose‐response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination with atorvastatin 10, 40, and 80 mg/day to hypercholesterolemic patients.